Mankind Pharma Q2 profit rises 38% to Rs 716 crore
In short
Mankind Pharma said its September-quarter profit rose 37.7% to ₹716 crore. Revenue from operations climbed to ₹4,337.9 crore from ₹3,697.2 crore a year earlier.
The company says strong business in India and overseas helped the result. It also expects the Armed Cell Therapeutics deal to improve research work, but the full effect is not stated.
What the reporting says
Mankind Pharma reported a 37.7% rise in net profit to ₹716 crore for the September quarter, according to a publisher summary. Revenue from operations increased to ₹4,337.9 crore from ₹3,697.2 crore a year earlier, with growth attributed to stronger domestic and international performance. The summary also says the acquisition of Armed Cell Therapeutics is expected to boost R&D, though the full integration impact is not stated.
Why it matters
Mankind Pharma reported September-quarter profit of ₹716 crore, up 37.7%, while revenue from operations rose to ₹4,337.9 crore from ₹3,697.2 crore. The publisher summary says domestic and international performance drove the growth, and it notes the Armed Cell Therapeutics acquisition may strengthen R&D. The reporting does not give management guidance or detail the acquisition timeline.